Notice of Interim Results
Avacta Group PLC will announce its unaudited interim results for the six months ended June 30, 2025, on September 30, 2025, and will deliver a live presentation via Investor Meet Company at 14:00 BST on the same day. The company also confirmed a change to the date, time, and location for the presentation of its abstract at the European Society for Medical Oncology (ESMO) Congress. The presentation, titled "A Phase I trial of FAP-Dox (AVA6000)..." with abstract number 964P, will now take place on October 19 at 12:00-12:45 in Hall 25.
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
LONDON AND PHILADELPHIA - September 15, 2025 - Avacta Group plc (AIM: AVCT) a life sciences company developing innovative, targeted oncology drugs, confirms it will announce its unaudited interim results for the six months ended June 30, 2025 ("HY25"), on September 30, 2025.
Christina Coughlin, Chief Executive Officer and Brian Hahn, Chief Financial Officer will also deliver a live presentation via Investor Meet Company at 14:00 BST on the day.
The presentation is open to all existing and potential shareholders.
| Investors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via: AVCT - AVACTA GROUP PLC | Investor Meet Company |
Questions can be submitted pre-event via the Investor Meet Company dashboard up until September 30 09:00 BST, or at any time during the live presentation.
ESMO Congress Update
The Company confirms that the date, time and location of the abstract being presented at the European Society for Medical Oncology (ESMO) Congress, taking place from October 17-21, 2025, has changed. The updated details are included below:
Title: A Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
Session Title: Developmental Therapeutics
Session Date and Time: 19 October, 12.00-12.45
Location: Hall 25
Abstract Presentation Number: 964P
Speaker: William D. Tap
| Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre | CISION® platform. pre | CISION® is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre | CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates. | |
| About the pre | CISION® Platform | |||
| The pre | CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre | CISION® platform harnesses this tumor specific protease to cleave pre | CISION® peptide drug conjugates and pre | CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients. |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.